Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 3/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1185913 | 0.85 | STAT3 (0.47) | STAT3GSK3BADRB2CNR1CNR2 | |
| SCHEMBL8097993 | 0.84 | STAT3 (0.46) | STAT3GSK3BADRB2CNR1CNR2 | |
| SCHEMBL1185837 | 0.83 | STAT3 (0.47) | STAT3GSK3BADRB2CNR1CNR2 | |
| SCHEMBL8101363 | 0.83 | GSK3B (0.57) | STAT3GSK3BHTTTSHRCASP1 | |
| SCHEMBL8091801 | 0.83 | STAT3 (0.46) | STAT3GSK3BADRB2CNR1CNR2 | |
| SCHEMBL1186154 | 0.81 | STAT3 (0.48) | STAT3ADRB2CNR1CNR2KDM4E | |
| SCHEMBL8094691 | 0.81 | STAT3 (0.48) | STAT3GSK3BADRB2CNR1CNR2 | |
| SCHEMBL8108264 | 0.80 | GSK3B (0.46) | STAT3GSK3BALDH1A1KMT2AHTT | |
| SCHEMBL8102086 | 0.80 | CNR1 (0.46) | STAT3GSK3BADRB2CNR1CNR2 | |
| SCHEMBL12873978 | 0.79 | STAT3 (0.48) | STAT3ADRB2KDM4EHPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203459-B1 | SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2016-03-16 | — | — | EP | disclosed |
| US-8901112-B2 | Spirocyclic aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8901112-B2 | Spirocyclic aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8476261-B2 | Spirocyclic aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8476261-B2 | Spirocyclic aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20110034436-A1 | SPIROCYCLIC AMINOQUINOLNES AS GSK-3 INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| WO-2009035684-A1 | SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS | ACTIVX BIOSCIENCES, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034436-A1 | SPIROCYCLIC AMINOQUINOLNES AS GSK-3 INHIBITORS | GSK3A, GSK3B, GSKIP | STAT3 1982/4885GSK3B 2/4885ADRB2 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.